Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Short-term Investments (2023 - 2026)

Prelude Therapeutics' Short-term Investments history spans 4 years, with the latest figure at $59.8 million for Q1 2026.

  • On a quarterly basis, Short-term Investments rose 1.69% to $59.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $59.8 million, a 1.69% increase, with the full-year FY2025 number at $68.0 million, down 43.9% from a year prior.
  • Short-term Investments hit $59.8 million in Q1 2026 for Prelude Therapeutics, down from $68.0 million in the prior quarter.
  • Over the last five years, Short-term Investments for PRLD hit a ceiling of $207.6 million in Q4 2023 and a floor of $7.4 million in Q3 2025.
  • Historically, Short-term Investments has averaged $104.2 million across 4 years, with a median of $94.5 million in 2024.
  • Biggest five-year swings in Short-term Investments: crashed 94.79% in 2025 and later rose 1.69% in 2026.
  • Tracing PRLD's Short-term Investments over 4 years: stood at $207.6 million in 2023, then crashed by 41.66% to $121.1 million in 2024, then plummeted by 43.9% to $68.0 million in 2025, then fell by 12.01% to $59.8 million in 2026.
  • Business Quant data shows Short-term Investments for PRLD at $59.8 million in Q1 2026, $68.0 million in Q4 2025, and $7.4 million in Q3 2025.